Lynx1 Capital Management LP bought TCRX
December 22, 2025 · Form 4 insider transaction
Lynx1 Capital Management LP bought 75,500 shares of TScan Therapeutics, Inc. at $0.90 per share, a transaction worth $68.0K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 1 day after the transaction.
Footnotes
The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.